Fulcrum Therapeutics (FULC) Net Equity Issued and Repurchased (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $21000.0 in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $21000.0 in Q1 2026; TTM through Mar 2026 was $4.2 million, a 282.47% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, up 51.75% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $21000.0, down from $3.8 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for FULC reached as high as $3.8 million in Q4 2025 and fell as low as $21000.0 in Q1 2026.
• Historically, Net Equity Issued and Repurchased has averaged $748666.7 across 5 years, with a median of $287000.0 in 2023.
• Across the five-year window, Net Equity Issued and Repurchased tumbled 96.08% in 2022 and surged 4480.72% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $267000.0 in 2022, then advanced by 7.49% to $287000.0 in 2023, then slumped by 71.08% to $83000.0 in 2024, then jumped by 4480.72% to $3.8 million in 2025, then sank by 99.45% to $21000.0 in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $21000.0 in Q1 2026, $3.8 million in Q4 2025, and $64000.0 in Q3 2025.